Physician profile
Arthur Gray
NPI 1770588873
$18,177.83
in general payments reported to CMS, 2019-2025
33 companies · $3,457 in 2025
The $3,457 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $1,114 · 2021: $2,381 · 2022: $2,954 · 2023: $2,964 · 2024: $3,558 · 2025: $3,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,658 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,657.95 |
| Education | $322.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,443.69 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,893.75 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $1,478.29 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $1,299.63 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $1,178.45 | 2020-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,077.28 | 2019-2025 | |
| Lilly USA, LLC | $1,034.11 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,001.30 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $864.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $854.12 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $731.90 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $544.66 | 2023-2024 | Vtama |
| Pfizer INC. | $544.33 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $377.92 | 2023-2025 | Zoryve |
| Incyte Corporation | $315.77 | 2021-2025 | Opzelura |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $280.49 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $213.56 | 2019-2025 | Cabtreo, Jublia |
| Biofrontera INC. | $153.86 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $131.44 | 2020-2025 | Nemluvio |
| Almirall LLC | $124.45 | 2019-2023 | Klisyri |
| Organon LLC | $119.57 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $109.97 | 2020-2021 | |
| Epi Health, LLC | $88.36 | 2019-2022 | |
| Genentech USA, INC. | $48.73 | 2019-2023 | Erivedge |
| Dusa Pharmaceuticals, INC. | $46.48 | 2019 | |
| Organogenesis INC. | $39.44 | 2025 | Apligraf |
| Botanix Sb INC | $36.08 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $34.38 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $31.88 | 2019 | |
| Prugen, INC. Pharmaceuticals | $28.32 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $20.73 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $15.23 | 2019 | |
| Stemline Therapeutics INC. | $15.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.